These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
137 related items for PubMed ID: 3607288
1. Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity. Bhalla K, MacLaughlin W, Cole J, Arlin Z, Baker M, Graham G, Grant S. Blood; 1987 Aug; 70(2):568-71. PubMed ID: 3607288 [Abstract] [Full Text] [Related]
2. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture. Grant S, Bhalla K, Arlin Z, Howe CW. Exp Hematol; 1990 Jan; 18(1):41-8. PubMed ID: 2298268 [Abstract] [Full Text] [Related]
4. Deoxycytidine stimulates the in vitro growth of normal CFU-GM and reverses the negative regulatory effects of acidic isoferritin and prostaglandin E1. Bhalla K, Cole J, MacLaughlin W, Baker M, Arlin Z, Graham G, Grant S. Blood; 1986 Nov; 68(5):1136-41. PubMed ID: 3464321 [Abstract] [Full Text] [Related]
5. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells. Grant S, Bhalla K, McCrady C. Leuk Res; 1991 Nov; 15(4):205-13. PubMed ID: 2030601 [Abstract] [Full Text] [Related]
7. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Graham G. Leukemia; 1988 Dec; 2(12):810-3. PubMed ID: 3264363 [Abstract] [Full Text] [Related]
8. Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells. Van Der Lely N, De Witte T, Muus P, Raymakers R, Preijers F, Haanen C. Exp Hematol; 1991 May; 19(4):267-72. PubMed ID: 2055291 [Abstract] [Full Text] [Related]
9. Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts. Reuter C, Schleyer E, Rolf C, Wörmann B, Büchner T, Hiddemann W. Leukemia; 1997 Apr; 11(4):561-71. PubMed ID: 9096697 [Abstract] [Full Text] [Related]
10. Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells. Grant S, Bhalla K, Gleyzer M. Leuk Res; 1986 Apr; 10(9):1139-46. PubMed ID: 2429121 [Abstract] [Full Text] [Related]
11. Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Safah H, Graham G. Exp Hematol; 1991 Aug; 19(7):669-73. PubMed ID: 1893953 [Abstract] [Full Text] [Related]
12. [Relationship between Ara-C sensitivity of leukemic-colony forming units (L-CFU) and [3H] deoxycytidine suicide test of L-CFU]. Umeda M, Shirai T. Nihon Ketsueki Gakkai Zasshi; 1989 May; 52(3):618-22. PubMed ID: 2618540 [Abstract] [Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Hiddemann W, Kiehl M, Zühlsdorf M, Busemann C, Schleyer E, Wörmann B, Büchner T. Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573 [Abstract] [Full Text] [Related]
14. Selective eradication of leukemic (L-CFU) versus normal (CFU-GM) myeloid progenitors in suspension culture utilizing a prolonged exposure to 1-B-D arabinofuranosylcytosine (Ara-C) and deoxycytidine (dCyd). Grant S, Howe C, Kuczynski T. Prog Clin Biol Res; 1990 Apr; 333():69-77. PubMed ID: 2309002 [No Abstract] [Full Text] [Related]
15. 2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity. Bhalla K, Birkhofer M, Li GR, Grant S, MacLaughlin W, Cole J, Graham G, Volsky DJ. Blood; 1989 Nov 01; 74(6):1923-8. PubMed ID: 2572282 [Abstract] [Full Text] [Related]
16. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia. Stiff PJ, Schulz WC, Bishop M, Marks L. Blood; 1991 Jan 15; 77(2):355-62. PubMed ID: 1985700 [Abstract] [Full Text] [Related]
17. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado AM, Jasiok M. Blood; 1991 Nov 15; 78(10):2674-9. PubMed ID: 1824260 [Abstract] [Full Text] [Related]
18. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Bhalla K, Nayak R, Grant S. Cancer Res; 1984 Nov 15; 44(11):5029-37. PubMed ID: 6091869 [Abstract] [Full Text] [Related]
19. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells. Bhalla K, Holladay C, Lutzky J, Ibrado AM, Bullock G, Jasiok M, Singh S. Gynecol Oncol; 1992 Apr 15; 45(1):32-9. PubMed ID: 1601333 [Abstract] [Full Text] [Related]
20. GM-CSF enhances sensitivity of leukemic clonogenic cells to long-term low dose cytosine arabinoside with sparing of the normal clonogenic cells. De Witte T, Muus P, Haanen C, Van der Lely N, Koekman E, Van der Locht A, Blankenborg G, Wessels J. Behring Inst Mitt; 1988 Aug 15; (83):301-7. PubMed ID: 3071344 [Abstract] [Full Text] [Related] Page: [Next] [New Search]